MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC

MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC

Abstract Background ROS1 tyrosine kinase inhibitors (TKIs) have demonstrated significant clinical benefit for ROS1+ NSCLC patients. However, TKI resistance inevitably develops through ROS1 kinase domain (KD) modification or another kinase driving bypass signaling. While multiple TKIs have been desig...

Full description

Bibliographic Details
Main Authors: Logan C. Tyler, Anh T. Le, Nan Chen, Hala Nijmeh, Liming Bao, Timothy R. Wilson, David Chen, Brian Simmons, Kristen M. Turner, Dean Perusse, Shailaja Kasibhatla, Jason Christiansen, Arkadiusz Z. Dudek, Robert C. Doebele
Format: Article
Language:English
Published: Wiley 2022-11-01
Series:Thoracic Cancer
Subjects:
drug resistance
entrectinib
MET
NSCLC
ROS1
Online Access:https://doi.org/10.1111/1759-7714.14656

Internet

https://doi.org/10.1111/1759-7714.14656

Similar Items